H

JAN 16 ZOUL	? /			
THAT ENT	TRANSMITTAL LET	TER	Case No. 10466/72	
Serial No.	Filing Date	Examiner	Group Art Unit	
09/904,938	July 12, 2001	To be assigned	1645	
nventor(s)				
Ashkenazi et al.				
Title of Invention				
SECRETED AND TRANS	MEMBRANE POLYPEPTIDES A	ND NUCLEIC ACIDS ENCODING	THE CAME	

SECKET	SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME												
TO THE COMMISSIONER FOR PATENTS													
Transmitted herewith is a Statement According to 37C.F.R. § 1.821(f); copy of Sequence Listing in computer readable form; copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures and return postcard.													
	Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously submitted.												
	A verified statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed.												
	Petition for amonth extension of time.												
\boxtimes	No additional fee is required.												
	The fee has been calculated as shown below:												
	Other Than Small Entity Small Entity												
1 10 10	1		T	T	Smair	I	7	Smail	Entity				
, pi	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra	Rate	Add'I Fee	or	Rate	Add'I Fee				
Total		Minus			x \$9=			x \$18=					
Indep.		Minus			x 42=			x \$84=					
First Pre	sentation of Mu	ltiple Dep. C	laim		+\$140=			+ \$280=					
					Total add'I fee	\$		Total add'I fee	\$				
	Please charge Deposit Account No. 23-1925 (BRINKS HOFER GILSON & LIONE) in the amount of \$ A duplicate copy of this sheet is enclosed.												
	A check in the amount of \$ to cover the filing fee is enclosed.												
\boxtimes	The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this communication or credit any overpayment to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.												
\boxtimes													
	Respectfully submitted,												
(Gregory M. Zinkl, Ph.D. () Registration No. 48,492												
P.O. BO CHICAG	HOFER GILSON X 10395 60, ILLINOIS 606 21-4200			Agent for Ap	plicant				÷				
I hereby certify that this correspondence is being deposited with the United States Postal Service as express mail, label no. EL 562415196US, with sufficient postage, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on													
Date: OU 1/0/67 Signature: J. Signature:													
rev. DecC	, lu To-c												



PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231 www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/904,938

07/12/2001

Avi Ashkenazi

P1618P2C35

CONFIRMATION NO. 3143

Paul E. Rauch, Ph.D. Brinks, Hofer, Gilson & Lione NBC Tower - Suite 3600 455 Cityfront Plaza Drive

Chicago, IL 60611-5599



FORMALITIES LETTER OC000000007108579*

Date Mailed: 11/21/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• A request to transfer the computer readable form from another application on file at the U.S. Patent and Trademark Office has been submitted as permitted by 37 C.F.R. 1.821(e). However, the request cannot be complied with since there is no compliant CRF present at the United States Patent and Trademark Office. Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY